Nilvanstomig

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameNilvanstomig
Drug Alias NameZG005粉针剂ZG-005
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-PD-1Anti-T cell immunoglobulin and ITIM domains
TargetsProgrammed cell death protein 1T cell immunoglobulin and ITIM domains
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGensun Biopharma Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSuzhou Zelgen Biopharmaceuticals Co LtdShanghai Zejing Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[11] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A